Skip to content

Author

P. Gelebart

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Reviving low-affinity glycan-targeting CAR with combinatorial design.

CD19CAR T cells demonstrate remarkable therapeutic efficacy in the treatment of B cell malignancies. A global limitation of conventional CD19CAR therapy is its mono-specificity. Thus, defining complementary targets to CD19 is critical to avoid target-dependent limitations. Alternatives to protein antigens include secon...

C. Forcados, H. Köksal, Eveline Scherer et al. · 0 citations
Open access Oct 2026

Combining TAG-72CAR with anti-MUC16CAR improves the potency of ovarian cancer treatment.

Ovarian cancer (OC) is typically associated with poor prognosis and high mortality. Chimeric antigen receptor (CAR) T-cell therapy offers a promising strategy, yet its application in solid tumours remains constrained by limited efficacy and on-target/off-tumour toxicities. We previously developed K101CAR T cells target...

Alicia Villatoro, Aurore Dougé, K. Krpina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.